Ralph Snyderman, MD

Professor of Medicine
James B. Duke Professor of Medicine
Chancellor Emeritus of Duke University
Campus mail 2424 Erwin Road, Suite 1101, Durham, NC 27705
Phone (919) 684-6637
Email address ralph.snyderman@duke.edu

Phagocytic leukocytes including neutrophils and macrophages play a critical role in immunologically mediated host defense and tissue destruction. These cells migrate to and become activated at sites of inflammation in response to chemoattractant factors, including -C5a, interleukin 8 (IL-8), formylated peptides (e.g. fMLP) Leukotriene B4(LTB4) and platelet activating factor (PAF). The responses of leukocytes to chemoattractants is mediated by G protein coupled receptors. The focus of this laboratory has been to define the mechanisms which regulate chemoattractant receptors activation, desensitization and priming. To study the mechanisms of leukocyte activation, we have developed genetic and biochemical techniques. We constructed epitope-tagged human formylpeptide, C5a, PAF, LTB4 and IL-8 receptor cDNAs and expressed receptors either singly or multiply in a cell line which mimics responses of human inflammatory cells. These RBL-2H3 cells are a basophilic cell line which endogenously contains thrombin receptors. Using this model system, we are studying desensitization, cross-desensitization and priming, a phenomenon whereby one stimulus leads to greatly enhanced responsiveness to a second stimulus. Our data have demonstrated an unexpected and interesting complexity in chemoattractant receptor phosphorylation and desensitization. We have defined kinases involved in receptor desensitization. Furthermore, we have identified motifs in the cytoplasmic tails of IL-8 and PAF receptors that appear to be critical for cell activation by their respective ligands. We have also identified a new form of chemoattractant receptor desensitization, termed class desensitization. A major effort of this laboratory is directed at defining the precise molecular events controlling leukocyte activation.

Clinical trials: None
Areas of expertise and national recognition: Immunology, Inflammation, Rheumatology and Medical Center Adminstration.

Education and Training

  • M.D., State University of New York at Brooklyn, 1197

Publications

Snyderman, R. A Chancellor's Tale: Transforming Academic Medicine. Duke University Press, November 4, 2016. (Monograph)

Scholars@Duke

Snyderman, R, and Spellmeyer, D. "Precision medicine: beyond genomics to targeted therapies." Personalized Medicine 13, no. 2 (March 2016): 97-100.

Full Text

Snyderman, R, Meade, C, and Drake, C. "Value of Personalized Medicine." JAMA 315, no. 6 (February 2016): 613-. (Letter)

PMID
26864420
Scholars@Duke

Snyderman, R. "Personalized medicine 2014: has healthcare been transformed?." Personalized Medicine 11, no. 4 (June 2014): 365-368.

Full Text

Simmons, LA, Wolever, RQ, Bechard, EM, and Snyderman, R. "Patient engagement as a risk factor in personalized health care: A systematic review of the literature on chronic disease." Genome Medicine 6, no. 2 (February 26, 2014).

Full Text

Simmons, LA, Wolever, RQ, Bechard, EM, and Snyderman, R. "Patient engagement as a risk factor in personalized health care: a systematic review of the literature on chronic disease." Genome medicine 6, no. 2 (January 2014): 16-.

PMID
24571651
Scholars@Duke

Snyderman, R. "Personalized health care in 2013: a status report on the impact of genomics." N C Med J 74, no. 6 (November 2013): 478-484.

PMID
24316769
Scholars@Duke

Snyderman, R. "Personalized health care: from theory to practice." Biotechnol J 7, no. 8 (August 2012): 973-979. (Review)

PMID
22180345
Full Text

Burnette, R, Simmons, LA, and Snyderman, R. "Personalized health care as a pathway for the adoption of genomic medicine." Journal of personalized medicine 2, no. 4 (January 2012): 232-240.

PMID
25562362
Scholars@Duke

Simmons, LA, Dinan, MA, Robinson, TJ, and Snyderman, R. "Personalized medicine is more than genomic medicine: confusion over terminology impedes progress towards personalized healthcare." PERSONALIZED MEDICINE 9, no. 1 (January 2012): 85-91.

Full Text

Pages